Amneal Pharmaceuticals (NYSE:AMRX) Issues Earnings Results, Misses Estimates By $0.01 EPS

Amneal Pharmaceuticals (NYSE:AMRX – Get Rating) issued its earnings results on Wednesday. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.13 by ($0.01), MarketWatch Earnings reports. Amneal Pharmaceuticals had a return on equity of 61.08% and a net margin of 0.68%. The company had revenue of $497.30 million during the quarter, compared to analyst estimates of $502.29 million. During the same period in the prior year, the business earned $0.19 earnings per share. Amneal Pharmaceuticals’s quarterly revenue was up .9% on a year-over-year basis. Amneal Pharmaceuticals updated its FY22 guidance to $0.80-0.85 EPS.

Shares of NYSE AMRX traded down $0.11 during midday trading on Friday, reaching $3.44. 8,875 shares of the company traded hands, compared to its average volume of 701,808. The company has a market cap of $1.04 billion, a price-to-earnings ratio of 39.44, a PEG ratio of 0.22 and a beta of 1.24. The stock has a 50-day moving average price of $4.10 and a 200 day moving average price of $4.52. Amneal Pharmaceuticals has a 52 week low of $3.26 and a 52 week high of $6.21. The company has a debt-to-equity ratio of 7.11, a current ratio of 2.35 and a quick ratio of 1.57.

Several analysts recently weighed in on AMRX shares. Barclays cut their price objective on shares of Amneal Pharmaceuticals from $8.00 to $7.00 in a research report on Thursday, April 28th. Zacks Investment Research upgraded Amneal Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. California State Teachers Retirement System raised its position in shares of Amneal Pharmaceuticals by 1.6% during the 4th quarter. California State Teachers Retirement System now owns 135,691 shares of the company’s stock worth $650,000 after buying an additional 2,187 shares in the last quarter. LPL Financial LLC raised its holdings in Amneal Pharmaceuticals by 8.1% during the fourth quarter. LPL Financial LLC now owns 41,775 shares of the company’s stock worth $200,000 after purchasing an additional 3,147 shares in the last quarter. Royal Bank of Canada lifted its position in Amneal Pharmaceuticals by 8.2% in the third quarter. Royal Bank of Canada now owns 52,999 shares of the company’s stock worth $283,000 after purchasing an additional 3,995 shares during the period. Rhumbline Advisers lifted its position in Amneal Pharmaceuticals by 3.7% in the fourth quarter. Rhumbline Advisers now owns 158,222 shares of the company’s stock worth $758,000 after purchasing an additional 5,688 shares during the period. Finally, Morgan Stanley boosted its stake in Amneal Pharmaceuticals by 8.4% during the 2nd quarter. Morgan Stanley now owns 167,329 shares of the company’s stock valued at $856,000 after purchasing an additional 13,005 shares in the last quarter. Hedge funds and other institutional investors own 38.54% of the company’s stock.

Amneal Pharmaceuticals Company Profile (Get Rating)

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Recommended Stories